PIN9 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) AND RIBAVIRIN (COPEGUS) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) CO-INFECTION
Nov 1, 2006, 00:00
10.1016/S1098-3015(10)63511-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)63511-5/fulltext
Title :
PIN9 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) AND RIBAVIRIN (COPEGUS) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) CO-INFECTION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63511-5&doi=10.1016/S1098-3015(10)63511-5
First page :
Section Title :
Open access? :
No
Section Order :
363